Recurrent Ovarian Carcinoma Recruiting Phase 2 Trials for Durvalumab (DB11714)

DBCOND0030000 (Recurrent Ovarian Carcinoma)Recruiting2 IdentifierTitlePurposeDrugs
NCT03026062Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerTreatment
NCT02953457Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationTreatment